Bristol-Myers Squibb Company Obtains Japan Approval For Baraclude, Treatment For Chronic Hepatitis B Patients

August 4, 2006 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Tokyo, Aug 3, 2006 (JCN) - Bristol-Myers Squibb Japan announced on July 26 that its Baraclude - generic name: entecavir - had been certifiied by Japan's Health, Labor and Welfare Ministry.

Twitter
LinkedIn
Facebook
Email
Print

FDA Approvals Asia

Bristol Myers Squibb Company